However, to fully realizethe benefit of dual PI4Kβ and PKG inhibitions for this series,further optimization will aim to improve potency against PfPKG, de-risk human host kinase targets including mTOR, investigateselectivity over other human protein and lipid kinases, and optimizesolubility for the delivery of potent drugs against malaria. This evidence concerns the gene PI4KB and malaria.